Wells Fargo analyst Stephen Baxter raised the firm’s price target on HCA Healthcare to $275 from $243 and keeps an Equal Weight rating on the shares. The firm notes HCA’s results were generally strong, and the company appears positioned for attractive EBITDA growth in 2024 and 2025. Wells is also increasing its estimates modestly.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCA:
- HCA Healthcare price target raised to $275 from $256 at Barclays
- HCA Healthcare price target raised to $325 from $310 at Truist
- HCA Healthcare price target raised to $315 from $283 at RBC Capital
- HCA Healthcare price target raised to $350 from $325 at Jefferies
- HCA Healthcare price target raised to $310 from $280 at Deutsche Bank